The current financial score of ProKidney Corp is 6.16. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 150.00K, representing a year-over-year decrease of 32.13%, while its net profit experienced a year-over-year decrease of 71.71%.
The current valuation score of ProKidney Corp is 8.00. Its current P/E ratio is -3.19, which is -73.27% below the recent high of -0.85 and -594.49% above the recent low of -22.16.
The current earnings forecast score of ProKidney Corp is 7.50. The average price target is 6.25, with a high of 12.00 and a low of 1.00.
The current price momentum score of ProKidney Corp is 4.50. Currently, the stock price is trading between the resistance level at 1.98 and the support level at 1.49, making it suitable for range-bound swing trading.
The current institutional shareholding score of ProKidney Corp is 3.00. The latest institutional shareholding proportion is 35.56%, representing a quarter-over-quarter increase of 22.48%. The largest institutional shareholder is James Simons, holding a total of 1.10M shares, representing 0.00% of shares outstanding, with 1370.48% increase in holdings.
The current risk assessment score of ProKidney Corp is 3.51. The company's beta value is 1.71. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.